Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Maria Gabriella Ferrandina Giovanni Scambia Manuela Ludovisi Giacomo Corrado |
| Publication date | March 17, 2008 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |